How can you save time and reduce our drug development and manufacturing costs?

I knew that traditional manufacture and release would make it impossible for us to clinically determine the correct nafamostat component of our drug product. Quotient Sciences explained to me how their Translational Pharmaceutics® platform could reduce our development timeline by defining a design space for ER release rate, ER/IR ratio, and nafamostat dose. Additionally, they could integrate real-time adaptive manufacturing with clinical testing to rapidly test the variables within the design space and optimize the nafamostat formulation.

Leveraging an integrated compounding pharmacy approach under the Translational Pharmaceutics® platform saved us over a million dollars because we didn’t need to invest in scaling up peptide synthesis. We were able to make just the right amount of drug product needed to achieve the results we were looking for.